Advisors Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $33.1M | Buy |
66,082
+828
| +1% | +$397K | 0.35% | 90 |
|
|
2026
Q1 | $32.1M | Buy |
65,254
+574
| +0.9% | +$312K | 0.37% | 89 |
|
|
2025
Q4 | $37.5M | Sell |
64,680
-51,865
| -45% | -$29.3M | 0.44% | 69 |
|
|
2025
Q3 | $56.5M | Buy |
116,545
+1,401
| +1% | +$652K | 0.7% | 43 |
|
|
2025
Q2 | $46.7M | Sell |
115,144
-11,867
| -9% | -$4.96M | 0.64% | 47 |
|
|
2025
Q1 | $63.2M | Buy |
127,011
+7,967
| +7% | +$4.31M | 0.98% | 24 |
|
|
2024
Q4 | $61.9M | Buy |
119,044
+3,462
| +3% | +$1.9M | 0.97% | 22 |
|
|
2024
Q3 | $71.5M | Buy |
115,582
+730
| +0.6% | +$432K | 1.16% | 15 |
|
|
2024
Q2 | $63.5M | Buy |
114,852
+3,683
| +3% | +$2.11M | 1.11% | 16 |
|
|
2024
Q1 | $64.6M | Buy |
111,169
+6,089
| +6% | +$3.42M | 1.18% | 13 |
|
|
2023
Q4 | $55.8M | Buy |
105,080
+2,483
| +2% | +$1.2M | 1.14% | 14 |
|
|
2023
Q3 | $51.9M | Buy |
102,597
+18,216
| +22% | +$9.71M | 1.32% | 11 |
|
|
2023
Q2 | $44M | Buy |
84,381
+3,954
| +5% | +$2.13M | 1.05% | 20 |
|
|
2023
Q1 | $46.4M | Sell |
80,427
-312
| -0.4% | -$176K | 1.2% | 13 |
|
|
2022
Q4 | $44.5M | Buy |
80,739
+877
| +1% | +$465K | 1.21% | 17 |
|
|
2022
Q3 | $42.7M | Buy |
79,862
+4,030
| +5% | +$2.26M | 1.14% | 20 |
|
|
2022
Q2 | $41.2M | Buy |
75,832
+3,309
| +5% | +$1.82M | 1.25% | 18 |
|
|
2022
Q1 | $42.8M | Buy |
72,523
+3,428
| +5% | +$1.97M | 1.17% | 19 |
|
|
2021
Q4 | $46.1M | Buy |
69,095
+2,469
| +4% | +$1.54M | 1.25% | 12 |
|
|
2021
Q3 | $38.1M | Buy |
66,626
+2,213
| +3% | +$1.21M | 1.16% | 20 |
|
|
2021
Q2 | $32.5M | Buy |
64,413
+6,116
| +10% | +$2.89M | 1.03% | 25 |
|
|
2021
Q1 | $26.6M | Buy |
58,297
+3,916
| +7% | +$1.87M | 0.93% | 32 |
|
|
2020
Q4 | $25.3M | Buy |
54,381
+1,971
| +4% | +$924K | 0.97% | 32 |
|
|
2020
Q3 | $23.1M | Sell |
52,410
-3,996
| -7% | -$1.65M | 1.08% | 28 |
|
|
2020
Q2 | $20.4M | Sell |
56,406
-7,488
| -12% | -$2.51M | 1.01% | 35 |
|
|
2020
Q1 | $18.1M | Buy |
63,894
+4,960
| +8% | +$1.56M | 1.15% | 29 |
|
|
2019
Q4 | $19.1M | Buy |
58,934
+3,320
| +6% | +$1.01M | 0.89% | 35 |
|
|
2019
Q3 | $16.2M | Sell |
55,614
-758
| -1% | -$217K | 0.88% | 40 |
|
|
2019
Q2 | $16.6M | Buy |
56,372
+496
| +0.9% | +$137K | 0.98% | 32 |
|
|
2019
Q1 | $15.4M | Sell |
55,876
-1,499
| -3% | -$373K | 0.96% | 37 |
|
|
2018
Q4 | $12.8M | Sell |
57,375
-1,537
| -3% | -$361K | 0.93% | 37 |
|
|
2018
Q3 | $14.4M | Sell |
58,912
-2,042
| -3% | -$470K | 0.94% | 41 |
|
|
2018
Q2 | $12.6M | Buy |
60,954
+2,157
| +4% | +$458K | 0.87% | 48 |
|
|
2018
Q1 | $12.1M | Buy |
58,797
+3,430
| +6% | +$720K | 0.92% | 44 |
|
|
2017
Q4 | $10.5M | Buy |
55,367
+25,943
| +88% | +$4.97M | 0.83% | 50 |
|
|
2017
Q3 | $5.57M | Sell |
29,424
-1,317
| -4% | -$239K | 0.45% | 71 |
|
|
2017
Q2 | $5.36M | Sell |
30,741
-784
| -2% | -$132K | 0.44% | 74 |
|
|
2017
Q1 | $4.84M | Buy |
31,525
+5,242
| +20% | +$801K | 0.42% | 78 |
|
|
2016
Q4 | $3.71M | Buy |
+26,283
| New | +$3.88M | 0.35% | 87 |
|
Other funds holding TMO
Advisors Capital Management's TMO Position: Q2 2026 in Review
Advisors Capital Management increased its Thermo Fisher Scientific (TMO) stake by 1.3% in Q2 2026, buying an estimated $397K and bringing the position to 66,082 shares worth $33.1M. The position accounts for 0.35% of the portfolio, ranked #90.
Advisors Capital Management first reported a position in TMO in Q4 2016 and has held it in 39 quarters since. The position peaked at $71.5M in Q3 2024. 2,603 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Advisors Capital Management held 66,082 shares of Thermo Fisher Scientific worth $33.1M as of Q2 2026.
- Advisors Capital Management bought 828 Thermo Fisher Scientific shares in Q2 2026, an estimated $397K.
- Thermo Fisher Scientific made up 0.35% of Advisors Capital Management's portfolio in Q2 2026, its #90 holding.
- Advisors Capital Management first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 39 quarters since.
- Advisors Capital Management's Thermo Fisher Scientific position peaked at $71.5M in Q3 2024.
- 2,603 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.